Login to Your Account

AACR 2014

Agios pops as phase I data set ‘Foundation’ for precision medicine

By Jennifer Boggs
Managing Editor

Monday, April 7, 2014
Deemed “fantastic” by a leukemia expert, phase I data presented by Agios Pharmaceuticals Inc. snagged the spotlight Sunday at the American Association for Cancer Research (AACR) meeting in San Diego, with isocitrate dehydrogenase-2 (IDH2)-targeting candidate AG-221 producing a complete remissions (CRs) in three of seven evaluable patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription